News

Radical resection trumps local excision in stage I CRC


 

AT THE ASA ANNUAL MEETING

"I think this will provide the high-quality evidence that we require to treat these patients with evidence-based principles," he added.

Discussant Dr. Conor P. Delaney praised Dr. Bhangu for presenting "a great study." He placed the findings in perspective.

"It’s important to remember that the disadvantage that you’re showing with local therapy is very similar in size to the benefit that all of medical oncology gives us, with all of the effort that we invest in medical oncology. So this is actually a very significant result," declared Dr. Delaney, professor of surgery and chief of the division of colorectal surgery at Case Western Reserve University, Cleveland.

Dr. Bhangu reported having no financial conflicts.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Third drug approved for metastatic, treatment-resistant GIST
MDedge Hematology and Oncology
Everolimus approval now includes prevention of liver transplant rejection
MDedge Hematology and Oncology
Alpha-fetoprotein useful marker in HCC
MDedge Hematology and Oncology
Surgery may be avoided in early rectal cancer
MDedge Hematology and Oncology
New blood test could identify early pancreatic cancer
MDedge Hematology and Oncology
Designer T cells take aim at liver metastases
MDedge Hematology and Oncology
TML data on bevacizumab for colorectal cancer 'validate practice in the community'
MDedge Hematology and Oncology
What's in a name: Is the moniker 'palliative care' too loaded?
MDedge Hematology and Oncology
Dexamethasone eases end-of-life cancer-related fatigue
MDedge Hematology and Oncology
Adjuvant therapy selection in gastric cancer still more art than science
MDedge Hematology and Oncology